Business · Companies · 38 mins ago
Celltrion leads biosimilar markets in major Asian countries
Celltrion says its biosimilars lead in major Asian markets for treatments of autoimmune diseases and cancer.
Biosimilars are medicines made to be highly similar to existing biological drugs.
The company says the position is based on market data from IQVIA and Celltrion.
Its Remsima product range treats autoimmune diseases and contains infliximab.
The available information gives no complete market-share figures for the countries mentioned.
Celltrion is expanding local direct sales and launching follow-up products, building on its current position.
These launches may broaden the company's range of biosimilar treatments in the region.
Celltrion leads biosimilar market share in major Asian countries for autoimmune disease treatments and cancer drugs, according to the article.
It is expanding the launch of follow-on products, using a direct-sales system in local markets.
The article cites Celltrion and pharmaceutical market research firm IQVIA as sources.
The market-share information is for the second quarter of this year.
- Who
- Celltrion.
- What
- It leads biosimilar market share in major Asian countries for autoimmune disease treatments and cancer drugs.
- When
- The market-share figures are for the second quarter of this year. The article was published on November 19, 2026.
- Where
- Major Asian countries; specific countries are not fully stated in the available article text.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Celltrion
- Market data period
- Second quarter of this year
- Research firm cited
- IQVIA
- Product named
- Remsima, an infliximab biosimilar
- Product category
- Autoimmune disease treatments and cancer drugs